Hermetica Superfood Encyclopedia
The Short Answer
Ganoderma tsugae produces two primary bioactive fractions — alcohol-soluble triterpenoids (Gt-TRE), including ganoderic acids A and B, which suppress NF-κB and JAK/STAT3 signaling, and alcohol-insoluble polysaccharides (Gt-PS), which bidirectionally modulate macrophage and T-cell immune responses. Preclinical data demonstrate that Gt-TRE suppresses Th2 cytokines IL-4 and IL-5 in primary CD4+ T cells at 5–50 µg/mL and that ganoderic acid B inhibits HIV-1 protease with an IC50 of 0.17 mM, while no human clinical trials have yet confirmed these effects.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordGanoderma tsugae benefits
Ganoderma tsugae — botanical close-up
Health Benefits
**Antiallergic Activity**
Gt-TRE reduces histamine release from mast cells and suppresses eosinophil recruitment and eotaxin production in airway models, suggesting utility in type I hypersensitivity and allergic asthma management.
**Immunomodulation**
Gt-PS enhances NF-κB-driven macrophage activation up to 16-fold at concentrations of 400–500 µg/mL while simultaneously boosting IL-2 production, supporting adaptive immune priming without overt pro-inflammatory overstimulation.
**Anti-inflammatory Effects**
Triterpenoid fractions inhibit NF-κB transcriptional activity in RAW264.7 macrophages and EL-4 T-cell lines, reducing downstream prostaglandin E2 and cytokine cascades associated with chronic inflammatory states.
**Potential Hepatoprotection**: Consistent with the broader Ganoderma genus, G
tsugae triterpenoids are studied for liver-protective properties attributed to antioxidant activity and modulation of inflammatory signaling pathways in hepatic tissue, though species-specific human data are absent.
**Anticancer Potential**
Ganoderic acid A inhibits the JAK/STAT3 oncogenic signaling pathway implicated in multiple solid tumors and hematological malignancies, with in vitro evidence suggesting cytostatic activity at pharmacologically relevant concentrations.
**Antiviral Properties**
Ganoderic acid B demonstrated inhibition of HIV-1 protease at an IC50 of 0.17 mM in biochemical assays, placing it among naturally occurring protease inhibitor scaffolds worthy of further medicinal chemistry investigation.
**5α-Reductase Inhibition**: Certain ganoderic acids isolated from G
tsugae inhibit 5α-reductase with an IC50 of approximately 10.6 µM, an enzyme central to androgen metabolism relevant to benign prostatic hyperplasia and androgenic alopecia.
Origin & History
Natural habitat
Ganoderma tsugae is a bracket fungus native to eastern North America and East Asia, where it grows predominantly on dying or dead hemlock trees (Tsuga species), earning it the common name Hemlock Varnish Shelf. It thrives in cool, temperate forest environments with high moisture and decaying coniferous wood, fruiting from late spring through summer. In Taiwan and parts of East Asia, it has been cultivated commercially on hemlock logs and via submerged fermentation technology by producers such as Yung-Kien Industry using strains like YK-01.
“Within East Asian traditional medicine, Ganoderma mushrooms collectively have been revered for over 2,000 years, referenced in classical Chinese pharmacopoeias such as the Shennong Bencao Jing under the category of 'superior herbs' associated with longevity, tonification of Qi, and liver protection. While Ganoderma lucidum (Lingzhi/Reishi) dominates the historical literature, G. tsugae has been used in Taiwanese and Chinese folk medicine as an accessible regional substitute, particularly in areas where hemlock forests are prevalent. Traditional preparations involved decocting dried fruiting bodies in water for extended periods, producing bitter, dark teas consumed to strengthen vitality and support the immune system. Modern scientific interest in G. tsugae was catalyzed in part by Taiwanese researchers in the late 20th century who sought to characterize the species distinct from G. lucidum, leading to systematic fractionation studies by institutions including Yung-Kien Industry.”Traditional Medicine
Scientific Research
The current evidence base for Ganoderma tsugae consists almost entirely of in vitro cell culture studies — including work in RBL-2H3 mast cells, EL-4 T-lymphoma cells, and RAW264.7 macrophages — and limited rodent models examining Th2 cytokine suppression and airway inflammation, with no published randomized controlled trials in humans specifically for this species. Genus-level Ganoderma research is considerably broader, encompassing hundreds of studies and several small clinical trials for Ganoderma lucidum, but these findings cannot be directly extrapolated to G. tsugae without species-specific confirmation. Submerged fermentation optimization studies have characterized polysaccharide yields of up to 1.68 g/L under defined conditions (28°C, pH 5.5, 120 rpm), providing reproducible starting material for future pharmacological investigations. Overall, the evidence quality is classified as preliminary-preclinical, and substantial investment in pharmacokinetic, toxicological, and human clinical trial research is required before any therapeutic claims can be substantiated.
Preparation & Dosage
Traditional preparation
**Dried Fruiting Body Powder**
1–3 g/day of raw mushroom powder, though G
No standardized human dose established; genus-level convention suggests . tsugae-specific dosing is unvalidated.
**Hot Water Extract (Polysaccharide-Rich)**
Fruiting bodies extracted with boiling water yield an alcohol-insoluble Gt-PS fraction; in vitro effective concentrations range from 100–500 µg/mL, with no confirmed oral bioequivalent.
**Alcohol Extract (Triterpenoid-Rich, Gt-TRE)**
128 g triterpenoids per 100 g dry material; in vitro activity observed at 5–50 µg/mL
Produced by ethanol/methanol fractionation of fruiting bodies; one commercial extract contained .
**Submerged Fermentation Mycelial Extract**
68 g/L exopolysaccharides; used in research-grade preparations by Yung-Kien Industry (YK-01 strain)
Optimized at 28°C, pH 5.5, 120 rpm; yields up to 1..
**Standardization**
No pharmacopoeial standard exists for G. tsugae; genus-level products are sometimes standardized to 10–30% polysaccharides or 4–6% triterpenes, but species-specific standards are lacking.
**Timing**
Traditional Ganoderma preparations are typically consumed with meals to reduce gastrointestinal sensitivity; no pharmacokinetic timing data exist for G. tsugae specifically.
Nutritional Profile
Ganoderma tsugae fruiting bodies contain predominantly complex polysaccharides (alcohol-insoluble fraction at approximately 0.39 g/100g in processed extracts) and triterpenoids (up to 128 g/100g in concentrated triterpenoid-rich extracts), alongside trace amounts of proteins, dietary fiber, and minerals typical of bracket fungi. The triterpenoid complement includes ganoderic acids A and B among over 140 characterized triterpenes across the Ganoderma genus, with lanostane-type tetracyclic triterpenoids constituting the primary bioactive scaffold. Polysaccharides in G. tsugae have an average molecular weight in the range of approximately 5.13 × 10^5 Da, consistent with high-molecular-weight beta-glucan and heteropolysaccharide structures that influence immune receptor binding and bioavailability. Ergosterol (provitamin D2) and various B vitamins including riboflavin and niacin are expected based on genus-wide analyses, though species-specific micronutrient quantification for G. tsugae has not been comprehensively published.
How It Works
Mechanism of Action
Gt-TRE triterpenoids, including ganoderic acids A and B, suppress Th2-polarized immune responses by inhibiting NF-κB transcriptional activity in macrophages and T cells, reducing downstream production of IL-4, IL-5, PGE2, and eotaxin while also blocking mast cell degranulation. Ganoderic acid A specifically interferes with the JAK/STAT3 signaling axis — a pathway constitutively active in numerous cancers — thereby disrupting tumor cell proliferation and survival signaling. Gt-PS polysaccharides exert a complementary, dose-dependent bidirectional effect: at moderate concentrations they enhance macrophage NF-κB activation and IL-2 secretion to stimulate innate and adaptive immunity, while suppressing IFN-γ at high doses, suggesting context-dependent immunosuppressive capacity. Ganoderic acid B acts as a competitive inhibitor of HIV-1 protease, and select ganoderic acids competitively inhibit 5α-reductase, indicating that steroidal triterpene scaffolds in G. tsugae interact directly with steroid-metabolizing and viral enzymatic active sites.
Clinical Evidence
No published human clinical trials specifically investigate Ganoderma tsugae as a distinct species; all outcome data originate from in vitro and animal studies. Preclinical models demonstrate statistically measurable suppression of Th2 cytokines (IL-4, IL-5) at 5–50 µg/mL Gt-TRE and macrophage NF-κB upregulation up to 16-fold with Gt-PS, but translational dose equivalents for humans remain undetermined. While Ganoderma lucidum has been the subject of small pilot RCTs for immune modulation in cancer patients, no comparable trials have been conducted with G. tsugae extracts, and effect sizes from lucidum trials cannot be assumed equivalent. Confidence in clinical benefit for G. tsugae is currently low, and practitioners should treat all reported bioactivities as hypothesis-generating rather than clinically validated.
Safety & Interactions
No formal toxicological studies, maximum tolerated dose determinations, or systematic adverse event data have been published specifically for Ganoderma tsugae in humans, making definitive safety characterization impossible at this time. Based on genus-level data from Ganoderma lucidum, potential concerns include mild gastrointestinal discomfort, dizziness, and dry mouth at higher doses, as well as theoretically additive effects with anticoagulants (e.g., warfarin) and antiplatelet agents due to observed platelet aggregation inhibition in related species. Immunomodulatory polysaccharide fractions may theoretically interact with immunosuppressive medications, warranting caution in organ transplant recipients and patients on calcineurin inhibitors or biologics. Safety during pregnancy and lactation has not been studied, and in the absence of data, use should be avoided in these populations; individuals with hemlock wood allergies should also exercise caution due to the fungus's substrate association.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Ganoderma tsugae MurrillHemlock Varnish ShelfHemlock ReishiGt-TRE (triterpenoid extract)Gt-PS (polysaccharide extract)
Frequently Asked Questions
What is Ganoderma tsugae and how does it differ from Ganoderma lucidum?
Ganoderma tsugae is a bracket mushroom that grows on hemlock trees in North America and East Asia, while Ganoderma lucidum (Reishi/Lingzhi) typically grows on deciduous hardwoods and is the more extensively researched species. Both produce similar triterpenoid and polysaccharide profiles, including ganoderic acids, but G. tsugae has a distinct species-level chemistry and substantially less human clinical trial data than G. lucidum. Practitioners and consumers should not assume that clinical outcomes from G. lucidum trials apply equally to G. tsugae without species-specific confirmation.
What are the main active compounds in Ganoderma tsugae?
The two principal bioactive fractions are alcohol-soluble triterpenoids (Gt-TRE) — including ganoderic acids A and B — and alcohol-insoluble polysaccharides (Gt-PS), primarily high-molecular-weight beta-glucan-type structures averaging approximately 5.13 × 10^5 Da. Ganoderic acid A inhibits JAK/STAT3 signaling with potential anticancer implications, while ganoderic acid B inhibits HIV-1 protease at an IC50 of 0.17 mM in biochemical assays. Concentrated triterpenoid extracts can contain up to 128 g of triterpenoids per 100 g of dry extract material.
Are there any human clinical trials on Ganoderma tsugae?
As of current literature, no published randomized controlled trials in humans have been conducted specifically using Ganoderma tsugae; all available efficacy data derive from in vitro cell studies and preclinical animal models. In vitro studies have shown that Gt-TRE suppresses Th2 cytokines IL-4 and IL-5 in CD4+ T cells at 5–50 µg/mL, and Gt-PS upregulates macrophage NF-κB activity up to 16-fold, but human pharmacokinetic and clinical outcome data remain entirely absent. This limits any therapeutic recommendations and places G. tsugae firmly in the preliminary evidence category.
Is Ganoderma tsugae safe to use, and are there any drug interactions?
No formal human safety or toxicology studies have been published for G. tsugae, so a definitive safety profile cannot be established. Based on genus-level data, potential interactions include additive effects with anticoagulants such as warfarin and antiplatelet drugs, as well as possible interference with immunosuppressive therapies including calcineurin inhibitors used by transplant patients. Until safety data are available, use during pregnancy, lactation, or alongside prescription immunomodulatory drugs should be avoided or undertaken only under medical supervision.
What is the recommended dosage of Ganoderma tsugae supplements?
No standardized or clinically validated dosage for Ganoderma tsugae has been established in human trials. Genus-level conventions for Ganoderma mushroom products suggest 1–3 g/day of dried fruiting body powder or extracts standardized to 10–30% polysaccharides or 4–6% triterpenes, but these benchmarks derive from Ganoderma lucidum research and may not be directly applicable to G. tsugae. In vitro bioactivity has been observed for Gt-TRE at 5–50 µg/mL and Gt-PS at 100–500 µg/mL, but oral bioavailability data necessary to translate these concentrations to human doses do not yet exist.
How does Ganoderma tsugae support immune function compared to other medicinal mushrooms?
Ganoderma tsugae contains polysaccharides (Gt-PS) that enhance macrophage activation up to 16-fold at optimal concentrations (400–500 µg/mL), while also boosting IL-2 production for T-cell mediated immunity. Unlike some mushrooms that focus primarily on general immune support, Ganoderma tsugae specifically targets both innate immunity (macrophages) and adaptive immunity (IL-2/T-cells), making it particularly effective for comprehensive immune modulation. This dual-pathway activation distinguishes it from single-mechanism mushroom supplements.
Can Ganoderma tsugae help with allergies and asthma symptoms?
Ganoderma tsugae extract (Gt-TRE) has demonstrated antiallergic activity by reducing histamine release from mast cells and suppressing eosinophil recruitment and eotaxin production in airway models. These mechanisms suggest potential utility in managing type I hypersensitivity reactions and allergic asthma by addressing the underlying inflammatory cascade rather than just symptom suppression. However, more human clinical trials are needed to establish efficacy and appropriate dosing for allergic conditions.
What forms of Ganoderma tsugae extract are most studied for immune and respiratory benefits?
Polysaccharide extracts (Gt-PS) and triterpene-rich extracts (Gt-TRE) are the most researched forms, with Gt-PS showing potent macrophage activation and Gt-TRE demonstrating antiallergic properties in in vitro and animal models. Standardized extracts containing both polysaccharides and triterpenes may offer complementary benefits for immune modulation and allergic response management. The specific extraction method and concentration of active compounds significantly impact the ingredient's biological activity.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w ganoderma-tsugae-hemlock-varnish-shelf curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
